SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Short Interest Up 41.6% in October

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) was the recipient of a significant growth in short interest in October. As of October 31st, there was short interest totalling 8,610,000 shares, a growth of 41.6% from the October 15th total of 6,080,000 shares. Based on an average trading volume of 535,900 shares, the short-interest ratio is currently 16.1 days.

Institutional Investors Weigh In On SELLAS Life Sciences Group

Several large investors have recently modified their holdings of SLS. Renaissance Technologies LLC purchased a new position in shares of SELLAS Life Sciences Group in the 2nd quarter valued at $39,000. XTX Topco Ltd bought a new stake in SELLAS Life Sciences Group during the third quarter valued at about $78,000. State Street Corp boosted its position in SELLAS Life Sciences Group by 30.2% during the third quarter. State Street Corp now owns 174,529 shares of the company’s stock valued at $218,000 after purchasing an additional 40,500 shares in the last quarter. Geode Capital Management LLC grew its stake in SELLAS Life Sciences Group by 17.1% in the third quarter. Geode Capital Management LLC now owns 605,191 shares of the company’s stock valued at $757,000 after purchasing an additional 88,183 shares during the last quarter. Finally, Anson Funds Management LP bought a new position in SELLAS Life Sciences Group in the third quarter worth about $992,000. Institutional investors own 17.38% of the company’s stock.

SELLAS Life Sciences Group Price Performance

Shares of SLS stock traded up $0.05 during mid-day trading on Friday, hitting $1.32. The stock had a trading volume of 861,803 shares, compared to its average volume of 1,071,800. SELLAS Life Sciences Group has a 12-month low of $0.50 and a 12-month high of $1.72. The firm’s 50-day moving average is $1.23 and its two-hundred day moving average is $1.26. The firm has a market capitalization of $84.92 million, a P/E ratio of -1.91 and a beta of 2.39.

SELLAS Life Sciences Group (NASDAQ:SLS) last released its quarterly earnings data on Tuesday, August 13th. The company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.03. Analysts expect that SELLAS Life Sciences Group will post -0.55 EPS for the current year.

SELLAS Life Sciences Group Company Profile

SELLAS Life Sciences Group, Inc, a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company’s lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer.